Literature DB >> 15795700

Eradication rate of Helicobacter pylori in dyspeptic patients.

Mohsen Amini1, Hossein Khedmat, Fatemeh Yari.   

Abstract

BACKGROUND: The eradication of Helicobacter pylori (HP) is dependent on several bacteriologic and geographic variables. Multiple-drug regimens have been tried in order to eradicate HPi; however, the optimal drug has not yet been found. MATERIAL/
METHODS: In this single-blind, randomized clinical trial, 245 dyspeptic patients with positive rapid urease tests or positive cultures for HP were entered in the study and randomly treated with one of 3 drug regimens A, B, or C for 14 days. Each regimen was administered to 76 patients. Regimen A consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + metronidazole 250 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid. Regimen B consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid. Regimen C consisted of omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + ciprofloxacin 500 mg bid. A urea breath test was performed 1-2 months after eradication.
RESULTS: Of the 245 patients, 228 completed their treatment course. 57% were male and 43% female. Eradication rates were 76.3%, 68.4%, and 67.1% in groups A, B, and C, respectively (P=0.05). The eradication rate of drug regimen A was greater than B in males (86% vs. 63%; p<0.05), and that of B was greater than C in females (76.7 vs. 53.6%; P<0.05).
CONCLUSIONS: The therapeutic regimen containing ciprofloxacin is preferable, although all drug regimens were less effective in Iran than in other parts of the world.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795700

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

Review 2.  Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.

Authors:  Marjan Mohammadi; Bahareh Attaran; Reza Malekzadeh; David Y Graham
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

Review 3.  Helicobacter pylori Infection in the general population: A Middle Eastern perspective.

Authors:  Hossein Khedmat; Reza Karbasi-Afshar; Shahram Agah; Saeed Taheri
Journal:  Caspian J Intern Med       Date:  2013

Review 4.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

5.  Efficacy of a "Rescue" Ciprofloxacin-Based Regimen for Eradication of Helicobacter pylori Infection after Treatment Failures.

Authors:  Maria Pina Dore; Vincenza Tadeu; Bianca Are; Ida Mura; Giuseppe Fanciulli; Giovannino Massarelli; Andrea Piana
Journal:  Gastroenterol Res Pract       Date:  2012-05-14       Impact factor: 2.260

6.  Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial.

Authors:  Jaime Natan Eisig; Tomás Navarro-Rodriguez; Ana Cristina Sá Teixeira; Fernando Marcuz Silva; Rejane Mattar; Decio Chinzon; Christiane Haro; Márcio Augusto Diniz; Joaquim Prado Moraes-Filho; Ronnie Fass; Ricardo Correa Barbuti
Journal:  Gastroenterol Res Pract       Date:  2015-05-04       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.